Publications

Section Newsletter Articles From Kate O’Súilleabháin

FTC v. Actavis, Inc.: Pay-for-delay settlements subject to rule of reason By Kate O’Súilleabháin June 2013 On June 17, in FTC v. Actavis, Inc., the U.S. Supreme Court determined that “pay-for-delay” settlements (also known as “reverse-payment settlements”) between drug manufacturers are subject to rule of reason antitrust scrutiny for purposes of determining whether they violate federal antitrust laws.
Editor’s comments By Kate O’Súilleabháin August 2012 An introduction to the issue from Editor Kate Ó Súilleabháin.
Recent developments in litigation on “pay-for-delay” settlements By Kate O’Súilleabháin August 2012 On July 16, a unanimous panel for the U.S. Court of Appeals for the Third Circuit ruled that any payment by a pharmaceutical company owning a patent to a generics drug manufacturer who agrees to delay entry into the market is prima facie evidence of an antitrust violation.
Editor’s comment By Kate O’Súilleabháin March 2012 An introduction to the issue from Editor Kate Ó Súilleabháin.
Editor’s note By Kate O’Súilleabháin September 2011 An introduction to the issue from Editor Kate Ó Súilleabháin.
Editor’s note By Kate O’Súilleabháin April 2011 An introduction to the issue from Editor Kate O Suilleabhain.
Editor’s note By Kate O’Súilleabháin February 2011 An introduction to the issue from Editor Kate O Suilleabhain.
Editor’s note By Kate O’Súilleabháin September 2010 An introduction to the issue from Editor Kate O Suilleabhain.

Spot an error in your article? Contact Sara Anderson at sanderson@isba.org. For information on obtaining a copy of an article,visit the ISBA Newsletters page.

Select a Different Author